ASAM's addiction guidelines will now surface inside an AI tool its users already have open. The American Society of Addiction Medicine and OpenEvidence announced a partnership on Oct. 28 that puts ASAM's clinical practice guidelines, treatment recommendations and implementation resources inside OpenEvidence's AI platform, where they will surface automatically when a clinician's query touches substance use - alongside the peer-reviewed literature the tool already cites, with links back to the source documents. The mechanics are unglamorous and that is the point. No new portal, no separate login, no continuing education module. The guidance arrives in the same window a clinician is already looking at while deciding what to prescribe. What the partnership actually covers. ASAM, founded in 1954, represents more than 8,000 physicians, clinicians and associated professionals. Its National Practice Guideline for opioid use disorder, in its 2020 focused update, revised 35 existing recommendations and added 13 new ones. That document is the closest thing the field has to a consensus standard for medication initiation, dosing and continuation, and it is not widely read outside addiction medicine. OpenEvidence, founded in 2021 and based in Florida, offers its platform free to verified U.S. clinicians. Its publishing partners include the New England Journal of Medicine, JAMA and the JAMA Network specialty journals, Nature Portfolio, Wiley and Sage. The company closed a $250 million Series D in January 2026, bringing twelve-month fundraising to nearly $700 million and its valuation to $12 billion. Stephen M. Taylor, ASAM's president, framed the deal as an access question: the society's guidelines, he said, aim to equip clinicians with high-quality, science-based guidance, and the collaboration is meant to make that guidance reachable by all healthcare professionals who may provide care for patients with addiction. Both organizations cited a figure of roughly 44.6 million Americans with a substance use disorder in 2025. Why retrieval is the whole point, and not the whole job. Divide one number by the other. Forty-four point six million people with a substance use disorder against 8,000 addiction medicine specialists works out to more than 5,500 patients per specialist, before counting the far larger group with risky use that never meets diagnostic criteria. OpenEvidence made the same argument more bluntly in its own announcement: addiction medicine has clear, specific guidance, and most of the clinicians who need it did not train in it. That arithmetic is why a guideline's location matters more than its quality. A recommendation that appears when a family physician types a question about buprenorphine induction reaches the person about to write the prescription. What the announcement does not resolve is the difference between retrieving a recommendation and applying one. An answer engine returns the passage that matches a query. The National Practice Guideline is a set of recommendations with conditions attached - who is eligible, what dose, what monitoring, what to do when the first attempt fails - and a retrieved sentence is a fragment of that structure. Three things are worth watching as the integration goes live: whether each recommendation appears with its strength and evidence rating rather than as bare prose, whether the platform displays the guideline's date so a clinician can tell a 2020 update from a superseded version, and what the interface does when the published literature and the society's guidance point in different directions. For now the practical effect is narrower than the press release implies and more useful than a new website would have been. A prescriber in a county with no addiction specialist is likelier to encounter ASAM's standard for medication-assisted treatment at the moment it is relevant, rather than never. Editorial Board LADC, LCPC, CASAC The Rainier Rehab editorial team consists of licensed addiction counselors, healthcare journalists, and recovery advocates dedicated to providing accurate, evidence-based information about substance abuse treatment and rehabilitation.

NYU Langone Health and OpenEvidence, an AI tool for doctors, announced a partnership to build OpenEvidence into NYU Langone's Epic electronic health record (EHR) system. Clinicians can ask complex clinical questions in natural language and get answers grounded in peer-reviewed medical literature, with patient context, without leaving their Epic workflow. The rollout covers NYU Langone's hospitals, its outpatient network, and its Family Health Centers. It also reaches students at NYU Grossman School of Medicine and NYU Grossman Long Island School of Medicine. NYU Langone handles 12.4 million outpatient visits and more than 421,000 emergency department visits a year across New York and Florida. "Putting OpenEvidence inside the chart at NYU Langone means the world's medical literature is now in the room for every one of the twelve million visits," said Daniel Nadler, OpenEvidence's founder and chief executive officer.

NYU Langone embeds OpenEvidence in Epic EHR for 12M annual visits - unite.ai. On October 29, 2026, NYU Langone Health and OpenEvidence announced a collaboration that embeds OpenEvidence's Patient Aware Clinical Intelligence in NYU Langone's Epic electronic health record, extending the medical AI platform across a health system that handles 12.4 million outpatient visits each year. How the Epic integration works. With the integration in place, a clinician at NYU Langone can pose a complex clinical question in natural language inside the Epic EHR workflow and receive an answer grounded in peer-reviewed medical literature that incorporates patient context. The announcement describes the approach as connecting peer-reviewed medical evidence to each patient's clinical record in support of the care teams delivering care across New York City, Long Island, and beyond. The announcement characterizes NYU Langone as one of the nation's premier academic health systems, ranked No. 1 in the nation for quality by Vizient, Inc., and describes OpenEvidence as the most popular AI for doctors in the United States. Through the integration, NYU Langone equips its clinical team to surface the best available medical evidence at the point of care. Scale of the NYU Langone deployment. NYU Langone handles 12.4 million outpatient visits and more than 421,000 emergency department visits annually, according to the announcement, spread across seven inpatient locations and more than 400 outpatient locations in the New York region and Florida. The Family Health Centers at NYU Langone - described as one of the nation's largest Federally Qualified Health Center networks - serve more than 100,000 patients a year through roughly 600,000 visits in Brooklyn and beyond. More than 6,000 physicians and faculty, over 2,000 residents and fellows, and more than 54,000 employees staff the system, which the announcement describes as one of the largest sources of care in the nation's most populous metropolitan area. Deployment covers the system's hospitals and ambulatory network as well as the Family Health Centers, and it includes medical trainees at NYU Grossman School of Medicine and NYU Grossman Long Island School of Medicine. Statements from NYU Langone and OpenEvidence. "At NYU Langone, we are committed to working with OpenEvidence to make the latest technology available to our clinicians in a safe and practical environment at scale," said Nader Mherabi, executive vice president, vice dean, and chief digital and information officer at NYU Langone Health. Daniel Nadler, founder and CEO of OpenEvidence, said NYU Langone cares for New Yorkers at a scale few institutions in the country can match and does so while setting the standard of care across specialties, describing New York as the place where American medicine goes to prove itself at scale. "Putting OpenEvidence inside the chart at NYU Langone means the world's medical literature is now in the room for every one of the twelve million visits this system supports each year," Nadler said, adding that the company is proud to be powering care in the nation's largest metropolis. Earlier 2026 health-system integrations. The NYU Langone deployment follows other health-system collaborations OpenEvidence announced in September and October 2026. On September 16, 2026, OpenEvidence and Memorial Sloan Kettering Cancer Center announced a two-way partnership pairing two integrations: OpenEvidence within MSK's Epic workflow, and MSK's OncoKB precision oncology knowledge base within OpenEvidence for providers outside MSK. According to that announcement, OncoKB became the first somatic cancer variant knowledge base partially recognized by the U.S. Food and Drug Administration in October 2021, and more than half of U.S. hematologist-oncologists use OpenEvidence for their most complex oncology questions. On September 22, 2026, OpenEvidence and the University of Texas Medical Branch announced an integration that places OpenEvidence inside UTMB's electronic health record, where clinicians sign in with their standard UTMB enterprise credentials and receive answers citing medical literature, clinical guidelines, and other sources. The integration went live at UTMB in March 2026, and the organizations said more than half of UTMB clinicians now actively use OpenEvidence for clinical decision support across hospitals on four campuses and more than 100 clinics across Southeast Texas. On October 1, 2026, AdventHealth and OpenEvidence announced a same-day rollout making OpenEvidence available to physicians, nurses, pharmacists, care managers, therapists, and other clinical roles across AdventHealth, integrated into existing workflows within the electronic health record system. That announcement frames the tool as supporting clinician expertise and accountability rather than replacing them, and states that every care decision remains rooted in professional judgment, the patient's individual circumstances, and the relationship among patients, families, and their care team.